Literature DB >> 29528874

High-Density Lipoprotein Functionality as a New Pharmacological Target on Cardiovascular Disease: Unifying Mechanism That Explains High-Density Lipoprotein Protection Toward the Progression of Atherosclerosis.

Elda Favari1, Michael J Thomas2, Mary G Sorci-Thomas3.   

Abstract

The formation of the atherosclerotic plaque that is characterized by the accumulation of abnormal amounts of cholesterol-loaded macrophages in the artery wall is mediated by both inflammatory events and alterations of lipid/lipoprotein metabolism. Reverse transport of cholesterol opposes the formation and development of atherosclerotic plaque by promoting high density lipoprotein (HDL)-mediated removal of cholesterol from peripheral macrophages and its delivery back to the liver for excretion into the bile. Although an inverse association between HDL plasma levels and the risk of cardiovascular disease (CVD) has been demonstrated over the years, several studies have recently shown that the antiatherogenic functions of HDL seem to be mediated by their functionality, not always associated with their plasma concentrations. Therefore, assessment of HDL function, evaluated as the capacity to promote cell cholesterol efflux, may offer a better prediction of CVD than HDL levels alone. In agreement with this idea, it has recently been shown that the assessment of serum cholesterol efflux capacity (CEC), as a metric of HDL functionality, may represent a predictor of atherosclerosis extent in humans. The purpose of this narrative review is to summarize the current evidence concerning the role of cholesterol efflux capacity that is important for evaluating CVD risk, focusing on pharmacological evidences and its relationship with inflammation. We conclude that HDL therapeutics are a promising area of investigation but strategies for identifying efficacy must move beyond the idea of simply raising static HDL-cholesterol levels and toward methods of measuring the dynamics of HDL particle remodeling and the generation of lipid-free apolipoprotein A-I (apoA-I). In this way, apoA-I, unlike mature HDL, can promote the greatest extent of cholesterol efflux relieving cellular cholesterol toxicity and the inflammation it causes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528874     DOI: 10.1097/FJC.0000000000000573

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  12 in total

1.  Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk.

Authors:  Christina Gkolfinopoulou; Faye Soukou; Ioannis Dafnis; Tahsin F Kellici; Despina Sanoudou; Thomas Mavromoustakos; Efstratios Stratikos; Angeliki Chroni
Journal:  Cell Mol Life Sci       Date:  2020-07-14       Impact factor: 9.261

2.  HDL flux is higher in patients with nonalcoholic fatty liver disease.

Authors:  Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-09-10       Impact factor: 4.310

3.  Diabetes Impairs Cellular Cholesterol Efflux From ABCA1 to Small HDL Particles.

Authors:  Yi He; Graziella E Ronsein; Chongren Tang; Gail P Jarvik; W Sean Davidson; Vishal Kothari; Hyun D Song; Jere P Segrest; Karin E Bornfeldt; Jay W Heinecke
Journal:  Circ Res       Date:  2020-08-21       Impact factor: 17.367

4.  Circulating HDL levels control hypothalamic astrogliosis via apoA-I.

Authors:  Anna Götz; Maarit Lehti; Elizabeth Donelan; Cynthia Striese; Sebastian Cucuruz; Stephan Sachs; Chun-Xia Yi; Stephen C Woods; Samuel D Wright; Timo D Müller; Matthias H Tschöp; Yuanqing Gao; Susanna M Hofmann
Journal:  J Lipid Res       Date:  2018-07-10       Impact factor: 5.922

5.  Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study.

Authors:  Elena M Yubero-Serrano; Juan F Alcalá-Diaz; Diego Gómez-Coronado; Jose Lopez-Miranda; Francisco M Gutierrez-Mariscal; Antonio P Arenas-de Larriva; Patricia J Peña-Orihuela; Ruth Blanco-Rojo; Javier Martinez-Botas; Jose D Torres-Peña; Pablo Perez-Martinez; Jose M Ordovas; Javier Delgado-Lista
Journal:  Cardiovasc Diabetol       Date:  2021-03-25       Impact factor: 9.951

6.  Lower or higher HDL-C levels are associated with cardiovascular events in the general population in rural China.

Authors:  Shasha Yu; Xiaofan Guo; Guang Xiao Li; Hongmei Yang; Liqiang Zheng; Yingxian Sun
Journal:  Lipids Health Dis       Date:  2020-06-25       Impact factor: 3.876

Review 7.  The Roles of Lipoprotein in Psoriasis.

Authors:  Chun-Ming Shih; Chang-Cyuan Chen; Chen-Kuo Chu; Kuo-Hsien Wang; Chun-Yao Huang; Ai-Wei Lee
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

Review 8.  Hashimoto Thyroiditis and Dyslipidemia in Childhood: A Review.

Authors:  Rade Vukovic; Aleksandra Zeljkovic; Biljana Bufan; Vesna Spasojevic-Kalimanovska; Tatjana Milenkovic; Jelena Vekic
Journal:  Front Endocrinol (Lausanne)       Date:  2019-12-10       Impact factor: 5.555

9.  Risk factors and outcomes of cardiovascular disease readmission within the first year after dialysis in peritoneal dialysis patients.

Authors:  Jianbo Li; Naya Huang; Zhong Zhong; Pema Joe; Dan Wang; Zhen Ai; Lisha Wu; Lanping Jiang; Fengxian Huang
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

10.  Verification and comparison of three prediction models of ischemic stroke in young adults based on the back propagation neural networks.

Authors:  Yuyang Chen; Yingqi Mao; Xiaoyun Pan; Weifeng Jin; Tao Qiu
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.